![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Oliver J.M. Kepley C.L. Ortega E. Wilson B.S.
Publisher: Elsevier
ISSN: 0162-3109
Source: Immunopharmacology, Vol.48, Iss.3, 2000-07, pp. : 269-281
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Ras Signaling Pathway Proteins as Therapeutic Targets
Current Pharmaceutical Design, Vol. 7, Iss. 16, 2001-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Vannacci A. Baronti R. Zagli G. Marzocca C. Pierpaoli S. Bani D. Passani M.B. Mannaioni P.F. Masini E.
European Journal of Pharmacology, Vol. 465, Iss. 3, 2003-04 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design, Vol. 18, Iss. 16, 2012-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
CYLD-Mediated Signaling and Diseases
Current Drug Targets, Vol. 16, Iss. 4, 2015-04 ,pp. :